J 2023

Sex and age differences in sST2 in cardiovascular disease

BEETLER, Danielle J, Katelyn A BRUNO, Damian N DI FLORIO, Erika J DOUGLASS, Swikriti SHRESTHA et. al.

Basic information

Original name

Sex and age differences in sST2 in cardiovascular disease

Authors

BEETLER, Danielle J, Katelyn A BRUNO, Damian N DI FLORIO, Erika J DOUGLASS, Swikriti SHRESTHA, Carsten TSCHOEPE, Madeleine W CUNNINGHAM, Jan KREJČÍ (203 Czech Republic, belonging to the institution), Julie DOBROVOLNÁ (203 Czech Republic, belonging to the institution), Sabine PANKUWEIT, Dennis M MCNAMARA, Eun-Seok JEON, van Linthout SOPHIE, Lori A BLAUWET, Leslie T Jr COOPER and DeLisa FAIRWEATHER

Edition

Frontiers in Cardiovascular Medicine, Lausanne, Frontiers Media SA, 2023, 2297-055X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.600 in 2022

RIV identification code

RIV/00216224:14110/23:00134703

Organization unit

Faculty of Medicine

UT WoS

000923390600001

Keywords in English

biomarkers; heart failure; myocardial infarct; coronary artery disease; cardiomyopathy; congestive heart failure

Tags

International impact, Reviewed
Změněno: 2/2/2024 08:48, Mgr. Tereza Miškechová

Abstract

V originále

AimsThe goal of this study was to determine whether sex and age differences exist for soluble ST2 (sST2) for several cardiovascular diseases (CVDs). MethodsWe examined sST2 levels using an ELISA kit for myocarditis (n = 303), cardiomyopathy (n = 293), coronary artery disease (CAD) (n = 239), myocardial infarct (MI) (n = 159), and congestive heart failure (CHF) (n = 286) and compared them to controls that did not have CVDs (n = 234). ResultsMyocarditis occurred in this study in relatively young patients around age 40 while the other CVDs occurred more often in older individuals around age 60. We observed a sex difference in sST2 by age only in myocarditis patients (men aged 38, women 46, p = 0.0002), but not for other CVDs. Sera sST2 levels were significantly elevated compared to age-matched controls for all CVDs: myocarditis (p <= 0.0001), cardiomyopathy (p = 0.0009), CAD (p = 0.03), MI (p = 0.034), and CHF (p < 0.0001) driven by elevated sST2 levels in females for all CVDs except myocarditis, which was elevated in both females (p = 0.002) and males (p <= 0.0001). Sex differences in sST2 levels were found for myocarditis and cardiomyopathy but no other CVDs and were higher in males (myocarditis p = 0.0035; cardiomyopathy p = 0.0047). sST2 levels were higher in women with myocarditis over 50 years of age compared to men (p = 0.0004) or women under 50 years of age (p = 0.015). In cardiomyopathy and MI patients, men over 50 had significantly higher levels of sST2 than women (p = 0.012 and p = 0.043, respectively) but sex and age differences were not detected in other CVDs. However, women with cardiomyopathy that experienced early menopause had higher sST2 levels than those who underwent menopause at a natural age range (p = 0.02). ConclusionWe found that sex and age differences in sera sST2 exist for myocarditis, cardiomyopathy, and MI, but were not observed in other CVDs including CAD and CHF. These initial findings in patients with self-reported CVDs indicate that more research is needed into sex and age differences in sST2 levels in individual CVDs.

Links

NU22-02-00418, research and development project
Name: Klinické a proteomické biomarkery predikující reverzní remodelaci levé komory u pacientů s nově zjištěnou dilatační kardiomyopatií
Investor: Ministry of Health of the CR, Subprogram 1 - standard